index

Covid-19

MSD support Ministry of Health effort in building a strong and productive community through vaccination.

Diabetes

Diabetes is one of MSD’s top therapeutic priorities and a point of passion for many colleagues at MSD, both personally and professionally.

Read on

Hepatitis C

For nearly 30 years, MSD has been at the forefront of the response to chronic HCV, and our team continues to work tirelessly to advance scientific knowledge of this significant global public health issue.

Read on

Infectious Disease

For more than 80 years, MSD has contributed to the discovery and development of novel medicines and vaccines to combat infectious disease. Today, MSD is a global leader in antimicrobials with a proud heritage, broad portfolio and innovative pipeline.

Read on

Oncology / Cancer

Today, every member of our team remains committed to smartly and collaboratively accelerating the drug development process and the speed with which we can bring forward new approaches to treat people with cancer.

Read on

Vaccine

Vaccines are one of the greatest public health success stories in history, and MSD has played its part in that story.

Read on

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.